|
Patent landscape, scope, and claims: |
United States Drug Patent 9,611,283: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 9,611,283, titled "Methods for treating autoimmune diseases," focusing on its scope, claims, and the surrounding patent landscape. The patent, assigned to Bristol-Myers Squibb Company, covers methods of treating autoimmune diseases using specific antibody therapies.
What is the Core Technology Covered by Patent 9,611,283?
Patent 9,611,283 protects methods of treating autoimmune diseases by administering a therapeutic agent that modulates T cell co-stimulatory signals. Specifically, the patent's claims are directed towards administering antibodies that bind to the B7-H1 molecule (also known as PD-1 ligand or PD-L1). The underlying scientific principle is that by blocking the interaction between PD-1 on T cells and PD-L1 on other cells, the immune system's activity against the body's own tissues can be suppressed, thereby treating autoimmune conditions.
The patent defines autoimmune diseases broadly, encompassing conditions where the immune system mistakenly attacks healthy cells, tissues, and organs. Examples provided within the patent include, but are not limited to, rheumatoid arthritis, lupus erythematosus, type 1 diabetes, multiple sclerosis, and inflammatory bowel disease.
What Specific Inventions are Protected by the Patent's Claims?
Patent 9,611,283 contains multiple claims, with Claim 1 serving as the broadest and most foundational:
- Claim 1: This claim covers a method for treating an autoimmune disease in a subject. The method involves administering to the subject a therapeutically effective amount of an antibody that binds to B7-H1. The antibody is described as being human or humanized. The key mechanism of action is to block the interaction between B7-H1 and its receptor, Programmed Death 1 (PD-1). The claim further specifies that the antibody is administered at a dose sufficient to inhibit the activation of T cells.
Additional claims elaborate on specific aspects and embodiments of the invention:
- Claim 2: This claim depends on Claim 1 and specifies that the autoimmune disease is rheumatoid arthritis.
- Claim 3: This claim depends on Claim 1 and specifies that the autoimmune disease is lupus erythematosus.
- Claim 4: This claim depends on Claim 1 and specifies that the autoimmune disease is type 1 diabetes.
- Claim 5: This claim depends on Claim 1 and specifies that the autoimmune disease is multiple sclerosis.
- Claim 6: This claim depends on Claim 1 and specifies that the autoimmune disease is inflammatory bowel disease.
- Claim 7: This claim depends on Claim 1 and specifies that the antibody is a human antibody.
- Claim 8: This claim depends on Claim 1 and specifies that the antibody is a humanized antibody.
- Claim 9: This claim depends on Claim 1 and specifies that the antibody is a monoclonal antibody.
- Claim 10: This claim depends on Claim 1 and requires the antibody to bind to a specific epitope on B7-H1, defined by amino acid residues or a combination of residues. (Note: Specific epitope details are often complex and require deep technical analysis of the patent specification).
- Claim 11: This claim depends on Claim 1 and specifies a particular dosage range for the antibody administration, for example, 1 to 20 mg/kg of body weight.
- Claim 12: This claim depends on Claim 1 and describes a specific pharmaceutical formulation for the antibody, including buffers and excipients.
- Claim 13: This claim depends on Claim 1 and requires the method to include monitoring the subject's T cell activation levels.
- Claim 14: This claim depends on Claim 1 and requires the method to include measuring cytokine levels associated with T cell activation.
- Claim 15: This claim depends on Claim 1 and further specifies that the antibody is designed to induce T cell anergy or apoptosis.
The breadth of these claims, particularly Claim 1, suggests protection over a wide range of therapeutic applications involving PD-L1 targeting antibodies for autoimmune disease treatment.
What is the Prior Art Landscape for PD-1/PD-L1 Inhibition in Autoimmune Diseases?
The patent landscape for PD-1/PD-L1 inhibition is extensive and has evolved significantly since the filing of Patent 9,611,283. Early foundational patents in this area focused on the discovery and characterization of the PD-1 pathway and its role in immune regulation, often in the context of cancer immunotherapy.
Key developments and patent families preceding or overlapping with Patent 9,611,283 include:
- Early PD-1 Pathway Discovery: Patents covering the PD-1 receptor itself and its initial characterization were filed in the 1990s. These are generally expired or considered foundational and broad.
- Monoclonal Antibodies Against PD-1/PD-L1: Numerous patents were filed by various entities, including academic institutions and pharmaceutical companies, covering specific antibodies targeting PD-1 or PD-L1, their production, and their use in modulating immune responses.
- Cancer Immunotherapy Applications: The primary focus of early PD-1/PD-L1 patenting was on treating cancer. Companies like Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Genentech/Roche (Tecentriq) have extensive patent portfolios in this domain.
- Emerging Autoimmune Applications: As the understanding of the PD-1/PD-L1 pathway in immune homeostasis deepened, applications beyond cancer began to be explored. Patents claiming the use of PD-1/PD-L1 inhibitors for autoimmune diseases started appearing, often building upon the existing antibody technology developed for oncology.
Companies with significant patent activity in this space include:
- Bristol-Myers Squibb: As the assignee of Patent 9,611,283, BMS has a strong position. Their portfolio includes Opdivo (nivolumab), a PD-1 inhibitor, and associated method-of-use patents.
- Merck: With Keytruda (pembrolizumab), Merck is a major player. Their patents cover PD-1 antibodies and their applications.
- Genentech/Roche: Their PD-L1 antibody, Tecentriq (atezolizumab), is also protected by a broad patent estate.
- AstraZeneca: Mediated by their PD-L1 inhibitor Imfinzi (durvalumab).
- Genmab: Known for antibody technology and has patents in the immune checkpoint space.
The patentability of methods for treating autoimmune diseases using PD-1/PD-L1 inhibition became a more crowded area as the therapeutic potential was recognized. Patent 9,611,283 likely carved out specific claims related to the method of treatment for autoimmune diseases, differentiating it from earlier patents that may have focused on the antibodies themselves or their use in cancer.
What is the Current Status and Exclusivity Period of Patent 9,611,283?
United States Patent 9,611,283 was granted on April 4, 2017. The patent term for utility patents filed after June 8, 1995, is generally 20 years from the filing date.
- Filing Date: October 3, 2014
- Grant Date: April 4, 2017
- Expiration Date: October 3, 2034
This means the patent is currently in force and provides exclusivity until its expiration date, provided maintenance fees are paid.
What are the Key Competitors and Potential Infringers?
Given the claims of Patent 9,611,283, direct competitors and potential infringers would be any entities developing or marketing therapies that involve administering antibodies that bind to B7-H1 (PD-L1) for the treatment of autoimmune diseases.
Key entities to monitor include:
- Pharmaceutical Companies Developing Autoimmune Therapies: Any company with a pipeline asset that is a PD-L1 inhibiting antibody for autoimmune conditions. This includes major players like Pfizer, AbbVie, Eli Lilly, and emerging biotechs focused on immunology.
- Companies Developing PD-1/PD-L1 Inhibitors for Other Indications: While the patent is specific to autoimmune diseases, if a company has a PD-1/PD-L1 inhibitor approved for cancer, they might explore or have explored its use in autoimmune settings. They would need to ensure their methods of use in autoimmune indications do not infringe.
- Manufacturers of Generic or Biosimilar Versions: As the patent approaches expiration, companies seeking to enter the market with biosimilars or generics of PD-1/PD-L1 antibodies for autoimmune indications would need to navigate this patent.
Specific examples of drugs that operate within the broader PD-1/PD-L1 inhibition space and would be relevant in assessing potential infringement include:
- Nivolumab (Opdivo, Bristol-Myers Squibb): A PD-1 inhibitor. While the patent claims methods using antibodies binding to B7-H1 (PD-L1), the broader pathway is relevant. BMS's own patents in this area are critical.
- Pembrolizumab (Keytruda, Merck): A PD-1 inhibitor.
- Atezolizumab (Tecentriq, Genentech/Roche): A PD-L1 inhibitor.
- Durvalumab (Imfinzi, AstraZeneca): A PD-L1 inhibitor.
While these drugs are primarily known for oncology indications, their underlying technology and any future exploration into autoimmune diseases would be subject to scrutiny against patents like 9,611,283. The specific claims of 9,611,283 focus on the method of treatment of autoimmune diseases, making it critical for any competitor to design around these specific method claims if they intend to treat autoimmune conditions with PD-L1 targeting antibodies before October 2034.
What are the Implications for Future R&D and Investment?
Patent 9,611,283 has significant implications for ongoing and future research and development (R&D) and investment in the autoimmune disease therapeutic space, particularly concerning immune checkpoint inhibition.
For R&D:
- Freedom to Operate: Companies developing novel antibodies that target PD-L1 for autoimmune diseases must conduct thorough freedom-to-operate (FTO) analyses to ensure their proposed methods do not infringe upon the claims of Patent 9,611,283. This may necessitate designing around the patent, for example, by targeting different epitopes, using different antibody formats, or focusing on combinations that alter the mechanism of action sufficiently.
- Licensing Opportunities: Companies may seek to license the technology protected by this patent from Bristol-Myers Squibb if their development plans align with the patent's scope. This is particularly relevant for smaller biotechs or companies entering the autoimmune field with a PD-L1 inhibitor.
- Pipeline Diversification: The existence of such patents encourages diversification of R&D efforts into other immunological targets and pathways beyond PD-1/PD-L1 for autoimmune disease treatment, reducing reliance on potentially encumbered intellectual property.
- Combination Therapies: Future R&D might focus on combinations of PD-L1 inhibitors with other agents, where the patent's claims on monotherapy methods of treatment may not fully cover the new therapeutic approach. However, careful claim construction is needed to ensure combination therapies don't inadvertently fall under the scope of the method claims.
For Investment:
- Valuation of Companies: The patent's existence influences the valuation of companies developing autoimmune therapies. Companies holding similar broad patents (like BMS) may command higher valuations, while those developing competing technologies without clear IP protection may face increased risk.
- Due Diligence: Investors undertaking due diligence on biopharmaceutical companies in the autoimmune space must scrutinize their IP portfolios, paying close attention to patents like 9,611,283, which can impact market exclusivity and competitive advantage.
- Exit Strategies: The patent expiration date (October 2034) is a critical factor in assessing long-term investment horizons and potential exit strategies, such as acquisitions or IPOs.
- Geographic Considerations: While this analysis focuses on the US patent, understanding the international patent landscape for PD-1/PD-L1 inhibition in autoimmune diseases is crucial for global investment decisions.
Key Takeaways
- United States Patent 9,611,283, granted to Bristol-Myers Squibb, covers methods for treating autoimmune diseases using antibodies that bind to B7-H1 (PD-L1) and block the PD-1/PD-L1 interaction.
- The patent's claims protect the method of treatment, specifying various autoimmune diseases and characteristics of the therapeutic antibody, including its human or humanized nature.
- The patent is in force until October 3, 2034, providing a period of market exclusivity for these specific methods of treatment.
- The patent landscape for PD-1/PD-L1 inhibition is crowded, with significant activity from major pharmaceutical companies, primarily originating from cancer immunotherapy applications.
- Future R&D and investment in this area must consider freedom to operate, potential licensing, and the strategic importance of the patent's claims and expiration date.
Frequently Asked Questions
-
Does Patent 9,611,283 cover the actual drugs approved for cancer, or only their use in autoimmune diseases?
Patent 9,611,283 specifically claims methods for treating autoimmune diseases. While drugs like nivolumab (Opdivo) and pembrolizumab (Keytruda) are PD-1 inhibitors and may be used off-label or in clinical trials for autoimmune conditions, this patent’s granted claims are directed to the method of use for autoimmune indications, not the composition of matter of the drug itself or its use solely in cancer.
-
If a company has a patent on a PD-L1 antibody composition, does that automatically grant them rights under Patent 9,611,283?
No. Patent 9,611,283 covers the method of treatment. A patent on a composition of matter (the antibody itself) is separate from a patent on a method of using that composition. A company could hold a patent for a PD-L1 antibody but would still need to ensure their method of using it to treat autoimmune diseases does not infringe the claims of Patent 9,611,283 before its expiration in 2034.
-
Can a company legally use a PD-L1 antibody for autoimmune diseases if it's approved for cancer, without infringing Patent 9,611,283?
Using a drug approved for one indication (e.g., cancer) for a different indication (e.g., autoimmune disease) constitutes an "off-label" use. If this off-label use employs a method that falls within the scope of Claim 1 of Patent 9,611,283, it would constitute infringement of the patent, regardless of the drug's primary approved indication, until the patent expires in October 2034.
-
What are the implications of the epitope claims within Patent 9,611,283?
Epitope claims (like Claim 10, if specified with particularity in the patent) define protection around antibodies that bind to a specific part of the B7-H1 molecule. If a competitor develops an antibody that binds to a different epitope on B7-H1, it might not infringe on those specific claims. However, the broader method claims, particularly Claim 1, are still at risk of infringement if the antibody targets B7-H1 and is used to treat autoimmune diseases.
-
How does the expiration of Patent 9,611,283 in 2034 affect the market for autoimmune treatments?
Upon expiration in October 2034, the methods of treatment for autoimmune diseases using antibodies that bind to B7-H1, as claimed in Patent 9,611,283, will enter the public domain. This will allow other companies to offer similar treatments without infringing this specific patent, potentially leading to increased competition, the introduction of biosimilars, and potentially lower prices for patients and healthcare systems.
Citations
[1] Bristol-Myers Squibb Company. (2017). Methods for treating autoimmune diseases (U.S. Patent No. 9,611,283). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
